LYMPHOPENIA IS AN INDEPENDENT RISK-FACTOR IN PATIENTS WITH LOW-RISK MDS ACCORDING TO THE IPSS-R

被引：0
|
作者：
Silzle, T. [1 ]
Schuler, E. [2 ]
Hildebrandt, B. [3 ]
Blum, S. [4 ]
Haas, R. [2 ]
Germing, U. [2 ]
机构：
[1] Cantonal Hosp St Gallen, Oncol Haematol, St Gallen, Switzerland
[2] Univ Hosp Dusseldorf, Dept Haematol Oncol & Clin Immunol, Dusseldorf, Germany
[3] Univ Hosp Dusseldorf, Inst Human Genet, Dusseldorf, Germany
[4] CHU Vaudois, Dept Oncol, Lausanne, Switzerland
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P664
引用
收藏
页码：263 / 263
页数：1
相关论文
共 50 条
  • [31] Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
    Silzle, Tobias
    Blum, Sabine
    Schuler, Esther
    Kaivers, Jennifer
    Rudelius, Martina
    Hildebrande, Barbara
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    BLOOD CANCER JOURNAL, 2019, 9 (8)
  • [32] Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
    Tobias Silzle
    Sabine Blum
    Esther Schuler
    Jennifer Kaivers
    Martina Rudelius
    Barbara Hildebrandt
    Norbert Gattermann
    Rainer Haas
    Ulrich Germing
    Blood Cancer Journal, 9
  • [33] Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry
    de Swart, Louise
    Smith, Alex
    Johnston, Tom
    Haase, Detlef
    Droste, Jackie
    Fenaux, Pierre
    Symeonidis, Argiris
    Sanz, Guillermo
    Hellstroem-Lindberg, Eva
    Cermak, Jaroslav
    Germing, Ulrich
    Stauder, Reinhard
    Georgescu, Otilia
    MacKenzie, Marius
    Malcovati, Luca
    Holm, Mette Skov
    Almeida, Antonio Medina
    Madry, Krzysztof
    Slama, Borhane
    Guerci-Bresler, Agnes
    Sanhes, Laurence
    Beyne-Rauzy, Odile
    Luno, Elisa
    Bowen, David
    de Witte, Theo
    BLOOD, 2013, 122 (21)
  • [34] The Natural History of Lower Risk MDS: Factors Predicting Progression to HighRisk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria
    Jain, Akriti G.
    Ball, Somedeb
    Aguirre, Luis E.
    Al Ali, Najla
    Kaldas, David
    Tinsley-Vance, Sara
    Kuykendall, Andrew T.
    Chan, Onyee
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami S.
    BLOOD, 2021, 138
  • [35] PERIPHERAL BLOOD WT1 EXPRESSION REFINES PROGNOSTIC INFORMATION FOR MDS PATIENTS WITHIN THE IPSS-R RISK CATEGORIES VERY LOW, LOWAND INTERMEDIATE
    Rautenberg, C.
    Pechtel, S.
    Geyh, S.
    Jaeger, P.
    Haas, R.
    Germing, U.
    Kobbe, G.
    Schroeder, T.
    LEUKEMIA RESEARCH, 2017, 55 : S149 - S149
  • [36] Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDSWith del(5q) in MDS-003 and MDS-004: A retrospective analysis
    Sekeres, M.
    Swern, A.
    Fenaux, P.
    Greenberg, P.
    Sanz, G.
    Bennett, J.
    Dreyfus, F.
    Cazzola, M.
    List, A.
    Garcia-Manero, G.
    Li, J. Shiansong
    Sugrue, M.
    LEUKEMIA RESEARCH, 2013, 37 : S69 - S70
  • [37] An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups
    Montoro, Julia
    Pomares, Helena
    Merchan, Brayan
    Molero, Antonieta
    Saumell, Silvia
    Alonso, Esther
    Fernandez, Monica
    Gallur, Laura
    Grau, Javier
    Salamero, Olga
    Blanco, Adoracion
    Varela, Anna
    Roldan, Elisa
    Sureda, Anna
    Bosch, Francesc
    Sangerman, Montserrat Arnan
    Valcarcel, David
    BLOOD, 2017, 130
  • [38] Are IPSS-R and IPSS Cytogenetic Risk Stratification Informative At the Time of Allogeneic Hematopoietic Cell Transplantation?
    Sachs, Zohar
    Dollan, Michelle
    De For, Todd E.
    Shune, Leyla
    Cooley, Sarah
    Weisdorf, Daniel J.
    Warlick, Erica D.
    Ustun, Celalettin
    BLOOD, 2012, 120 (21)
  • [39] Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine
    Cluzeau, Thomas
    Mounier, Nicolas
    Karsenti, Jean-Michel
    Richez, Valentine
    Legros, Laurence
    Gastaud, Lauris
    Garnier, Georges
    Re, Daniel
    Montagne, Nathalie
    Gutnecht, Jean
    Fuzibet, Jean Gabriel
    Auberger, Patrick
    Raynaud, Sophie
    Cassuto, Jill-Patrice
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (09) : 780 - 783
  • [40] Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category
    Calvo, Xavier
    Arenillas, Leonor
    Luno, Elisa
    Senent, Leonor
    Alonso, Esther
    Ramos, Fernando
    Ardanaz, Maria Teresa
    Pedro, Carme
    Tormo, Mar
    Marco, Victor
    Montoro, Julia
    Diez-Campelo, Maria
    Brunet, Salut
    Arrizabalaga, Beatriz
    Xicoy, Blanca
    Andreu, Rafael
    Bonanad, Santiago
    Jerez, Andres
    Nomdedeu, Meritxell
    Ferrer, Ana
    Sanz, Guillermo
    Florensa, Lourdes
    BLOOD, 2016, 128 (22)
12345